Floatz logo

Semaglutide

Type 2 Diabetes Mellitus

Shanghai Jiao Tong University School of Medicineprotein_peptidePhase 4 / ApprovedActive
BBB
78/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
77/ 100
Competitive Position
81/ 100

Competitive context

134 Active assets in the Type 2 Diabetes Mellitus cohort.

Asset / SponsorPhaseRating
Liraglutide
RenJi Hospital
Phase 4BBB
Dapagliflozin
Bhavya Bhavya, MD
Phase 4BBB
Cotadutide
AstraZeneca
Phase 2BBB
Exenatide
Vivani Medical, Inc
Phase 4BBB
Metformin
Myopharm Limited
Phase 4BBB

View all 49 →

Same molecule, other indications

Semaglutide is also rated in:

metabolic diseaseActive
A
Indicative · Phase 4
81 / 100
View asset →
polycystic ovary syndromeActive
BBB
Indicative · Phase 4
79 / 100
View asset →
prediabetes syndromeActive
BBB
Indicative · Phase 4
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →